EE2

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

2017 – Recap of Warning Letters, Import Alerts and Non-Compliances

Data integrity continued to be a hot topic in the pharmaceutical industry through 2017. According to

Mid-2017 Recap of FDA Warning Letters, Import Alerts & EU Non-Compliances

Last year, data integrity was a hot topic of discussion in the pharmaceutical industry. According t

FDA problems at Pfizer’s US facility continue; China FDA joins ICH

This week in our compliance round up, we look at the continuing problems at Pfizer’s McPherson

J&J’s diabetes drug reduces heart risk at the cost of toes; Google’s AI eye doctor initiative

This week in Phispers, we bring you news on J&J’s Invokana, a drug that reduces heart risk

GSK, Google form first bioelectronics firm; 11 generic companies benefit from the Teva Allergan deal

This week, Phispers brings to you the details of the bioelectronics firm formed by GSK and Google. T